Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 11/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.71 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.66 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GABRP | O00591 | 1/20 | 0.61 |
| ▸ | GABRD | O14764 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GABRE | P78334 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334382 | 0.91 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL11094088 | 0.89 | GABRG2 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10365966 | 0.89 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10812787 | 0.88 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iomazenil (123I) SCHEMBL29374678 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9745968 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iomazenil SCHEMBL29385986 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iomazenil (123I) SCHEMBL17022271 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7329697 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iomazenil SCHEMBL41658 | 0.88 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| EP-4247386-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022109052-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20210023091-A1 | TREATMENT OF CONDITIONS ASSOCIATED WITH MYOTONIC DYSTROPHY | EMORY UNIVERSITY | 2021-01-28 | — | — | US | claimed |
| US-10716779-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2020-07-21 | — | — | US | claimed |
| US-20190083465-A1 | Methods And Compositions For Treating Foot Or Hand Pain | SANDERS JENNIFER L (US) | 2019-03-21 | — | — | US | claimed |
| US-10195180-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2019-02-05 | — | — | US | claimed |
| WO-2018209119-A1 | TREATMENT OF CONDITIONS ASSOCIATED WITH MYOTONIC DYSTROPHY | EMORY UNIVERSITY (US) | 2018-11-15 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-4346032-A | ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346034-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346031-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | GABRA1 879/4885GABRG2 1092/4885GABRB3 387/4885 |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | GABRA1 2361/4885GABRG2 3369/4885GABRB3 1255/4885 |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRA1 8/4885GABRG2 14/4885GABRB3 9/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | GABRA1 1184/4885GABRG2 1329/4885GABRB3 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.